Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH

Cancer Research

Volumn 57, Issue 21, 1997, Pages 4811-4816

  Gabr, Attia ^a,b   Kuin, Annemieke ^a   Aalders, Marjanka ^a   El Gawly, Hoda ^b   Smets, Lou A ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CAMPTOTHECIN; ETOPOSIDE; GLUCOSE; GYRASE INHIBITOR; TOPOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PH; CELL SURVIVAL; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; INCUBATION TIME; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DNA, NEOPLASM; HYDROGEN-ION CONCENTRATION; LEUKEMIA L1210; MICE; MICE, INBRED C3H; TOPOTECAN;

EID: 0030856115     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kennedy, K. A., McGurl, J. D., Leondaridis, L., and Alabaster, O. pH dependence of mitomycin C induced cross-linking activity in EMT26 tumor cells. Cancer Res., 45: 3541-3547, 1985.
2. Sieman, D. W., Chapman, M., and Beikirch, A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int. J. Radiat. Oncol. Biol. Phys., 20: 287-289, 1991.
3. Atema, A., Buurman, K. J., Noteboom, E., and Smets, L. A. Potentiation of DNA-adduct formation and cytotoxicity of platinum containing drugs by low pH. Int. J. Cancer, 54: 166-172, 1993.
4. Jähde, E., and Rajewsky, M. F. Tumor-selective modification of cellular microenvironment in vivo: effect of glucose infusion on the pH in normal and malignant rat tissues. Cancer Res., 42: 1505-1512, 1982.
5. Kuin, A., Smets, L., Volk, T., Paans, A., Adams, G., Atema, A., Jähde, E., Maas, A., Rajewsky, M. F., Visser, G., and Wood, P. Reduction of intratumoral pH by the mitochondrial inhibitor m-iodobenzylguanidine and moderate hyperglycemia. Cancer Res., 54: 3785-3792, 1994.
6. Newell, K., Wood, P., Stratford, I., and Tannock, T. Effects of agents which inhibit the regulation of intracellular pH on murine solid tumours. Br. J. Cancer, 66: 311-317, 1992.
7. Tannock, I. F., and Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res., 49: 4373-4384, 1989.
8. Song, C. W., Lyons, J. C., and Luo, Y. Intra and extracellular pH in solid tumours: influence on therapeutic response. In: B. A. Teicher (ed.), Mechanisms of Drug Resistance in Oncology, pp. 25-52. New York: Marcel Dekker, 1993.
9. Wood, P. J., Samson, J. M., Newell, K., Tannock, I. F., and Stratford, I. J. Reduction of tumour intracellular pH and enhancement of melphalan cytotoxicity by the ionophore nigericin. Int. J. Cancer, 60: 264-268, 1995.
10. Yamagata, M., and Tannock, I. F. The chronic administration of drugs that inhibit the regulation of intracellular pHi in vitro and anti-tumour effects. Br. J. Cancer, 73: 1328-1334, 1996.
11. Beijnen, J. H., Smith, B. R., Keijer, W. J., van Gijn, R., Ten Bokkel Huinink, W. W., Vlasveld, L., Rodenhuis, S., and Underberg, W. J. High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J. Pharm. Biomed. Anal., 8: 789-794, 1990.
12. Fassberg, J., and Stella, V. J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci., 81: 676-684, 1992.
13. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong, S-M., Bartus, J. O., Johnson, R. K., and Kingsbury, W. D. Modification of the hydroxy-lactone ring of camptothecin: inhibition of mammalian topoisomerase 1 and biological activity. J. Med. Chem., 32: 715-720, 1989.
14. Burke, T. G., Mishra, A. K., Wani, M. C., and Wall, M. E. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry, 32: 5352-5364, 1993.
15. Burke, T. G., and Mi, Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal. Biochem., 212: 285-287, 1993.
16. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
17. Teicher, B. A., Holden, S. A., Khandakar, V., and Herman, T. S. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor. J. Cancer Res. Clin. Oncol., 119: 645-651, 1993.
18. Lim, M., Liu, L. F., Jacobson-Kram, D. J., and Williams, J. R. Induction of sister chromatid exchanges by inhibitors of topoisomerases. Cell Biol. Toxicol., 2: 485-494, 1986.
19. Smets, L. A., Loesberg, C., Janssen, M., and Van Rooij, H. Intracellular inhibition of mono(ADP-ribosylation) by meta-iodobenzylguanidine: specificity, intracellular concentration and effects on glucocorticoid-mediated cell lysis. Biochim. Biophys. Acta, 1054: 49-55, 1990.
20. Holm, C., Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49: 6365-6368, 1989.
21. Hasuda, K., Lee, C., and Tannock, I. F. Antitumour activity of nigericin and 5-(N-ethyl-N-isopropyl amiloride): an approach to therapy based on cellular acidification and the inhibition of regulation of intracellular pH. Oncol. Res., 6: 259-268, 1994.
22. Giovanella, B. C., Stehlin, J. S., Wall, M. C., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046-1048, 1989.
23. Potmesil, M. Camptothecins. From bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994.
24. Husain, I., Mohler, J. L., Seigler, H. F., and Besterman, J. M. Elevation of topoisomerase I messenger RNA, protein and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res., 54: 539-546, 1994.
25. Burris, H. A., III, Hanauske, A. R., Johnson, R. K., Marshall, M. H., Kuhn, J. G., Hilsenbeck, S. G., and Von Hoff, D. D. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J. Natl. Cancer Inst., 84: 1816-1820, 1994.
26. Chen, A. Y., Yu, C., Potmesil, M., Wall, M. E., Wani, M. C., and Liu, L. F. Camptothecin overcomes MDR-mediated resistance in human KB carcinoma cells. Cancer Res., 51: 6039-6044, 1991.
27. Hendricks, C. B., Rowinsky, E. K., Grochow, L. B., Donehower, R. C., and Kaufmann, S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res., 52: 2268-2278, 1992.
28. Guarino, A. M., Andersen, J. B., Starkweather, D. K., and Chignell, C. F. Pharmacologic studies of camptothecin (NSC-100880): distribution, plasma protein binding, and biliary excretion. Cancer Chem. Rep., 57: 125-140, 1973.
29. Van Warmerdam, L. J., Verweij, J., Schellens, J. H., Rosing, H., Davies, B. E., de Boer-Dennert, M., Maes, R. A., and Beijnen, J. H. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol., 35: 237-245, 1995.
30. Mi, Z., and Burke, T. G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry. 33: 10325-10336, 1994.
31. Mikkelsen, R. B., Asher, C., and Hicks, T. Extracellular pH, transmembrane distribution and cytotoxicity of chlorambucil. Biochem. Pharmacol., 34: 2531-2534, 1985.
32. Jensen, P. B., Sorensen, B. S., Sehested, M., Grue, P., Demant, E. J., and Hansen, H. H. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res., 54: 2959-2963, 1994.